Erectile Dysfunction News and Research

Latest Erectile Dysfunction News and Research

American Medical Systems fourth quarter sales increase 0.7% to $147.0 million

In anticipation of presenting at the JP Morgan Healthcare Conference on January 11, 2011, American Medical Systems Holdings, Inc. reported today preliminary sales of $147.0 million for the fourth quarter of 2010, a 0.7 percent increase over sales of $146.0 million in the comparable quarter of 2009.

11 Jan 2011

Elis granted exclusive rights to market Apricus Bio's Vitaros in the Gulf and part of the Middle East

Apricus Biosciences, Inc. and Elis Pharmaceuticals, announced today that the two companies have entered into a licensing agreement granting Elis the exclusive rights to market Apricus Bio's new drug for erectile dysfunction, Vitaros®, in the Gulf and part of the Middle East. "This new agreement is the next step in our strategy of seeking to partner Vitaros in more than 100 countries around the world," said Dr. Bassam Damaj, President and Chief Executive Officer of Apricus Bio.

5 Jan 2011

FDA approves Endo's FORTESTA Gel for low testosterone

Endo Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved FORTESTA Gel for the treatment of low testosterone, or 'Low T,' also known as hypogonadism. Symptoms associated with Low T include erectile dysfunction and decreased sexual desire, fatigue and loss of energy, mood depression, regression of secondary sexual characteristics and osteoporosis.

29 Dec 2010

VIVUS seeks marketing approval of QNEXA in the EU

VIVUS, Inc. today announced that the company filed a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) for QNEXA® (phentermine/topiramate) Controlled Release Capsules in the European Union (EU). The proposed indication in the EU is for the treatment of obesity, including weight loss and maintenance of weight loss, and should be used in conjunction with a mildly hypocaloric diet.

20 Dec 2010

VIVUS submits briefing document to FDA in effort to secure regulatory approval for QNEXA

VIVUS, Inc. today announced that the company, as part of its continuing effort to secure regulatory approval for QNEXA® in the U.S., submitted a briefing document to the Food and Drug Administration (FDA) designed to address items in the FDA's Complete Response Letter (CRL), issued on October 28, 2010. The company also announced that the Endocrine and Metabolic Division of the FDA has granted VIVUS a meeting in the second half of January 2011 to discuss the content of the proposed resubmission.

14 Dec 2010

Man Up Now capsules can dangerously lower blood pressure

Product marketed for sexual enhancement contains potentially dangerous ingredient The U.S. Food and Drug Administration is warning consumers not to use Man Up Now capsules, marketed as a dietary supplement for sexual enhancement, because they contain a variation of an active drug ingredient found in Viagra that can dangerously lower blood pressure.

13 Dec 2010

VIVUS reports positive results from avanafil phase 3 study in erectile dysfunction

VIVUS, Inc. today announced positive results from TA-314, a phase 3 pivotal open-label safety study of avanafil, an investigational drug for the treatment of erectile dysfunction (ED). The study met all primary endpoints by demonstrating improvement from baseline in erectile function as measured by the Sexual Encounter Profile (both SEP2 and SEP3) and improvements in the International Index of Erectile Function (IIEF).

7 Dec 2010

Apricus announces publication of NexACT technology data in Pharmaceutics Journal

Apricus Biosciences, Inc., announced today that the International Journal of Pharmaceutics, a peer reviewed journal, has published new data on the NexACT technology in their November 2010 issue, based on research conducted by, and at, the Ernest Mario School of Pharmacy, Rutgers-The State University of New Jersey in Piscataway, NJ.

30 Nov 2010

Merck announces initial results from ISENTRESS Phase III study in HIV-1

Merck today reported initial results from the Phase III study investigating the efficacy and safety of a treatment regimen including ISENTRESS® (raltegravir) Tablets once daily in treatment-naïve adult patients infected with HIV-1. ISENTRESS is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-naïve and treatment-experienced adults.

29 Nov 2010

Apricus files protocol of PrevOnco Phase 3 clinical trial for FDA SPA program

Apricus Biosciences, Inc., today announced that it has filed the protocol for a proposed Phase 3 clinical trial of PrevOnco, its proprietary treatment for hepatocellular carcinoma (liver cancer), with the U.S. Food and Drug Administration (FDA).

23 Nov 2010

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

NexACT technology improves oral delivery of five small molecule drugs

Apricus Biosciences, Inc., today announced data from animal studies showing that the NexACT technology significantly improved the oral delivery of five small molecule drugs tested, with the best improvements up to 20-fold, in terms of improvement in absorption.

20 Nov 2010

VIVUS closes sale of MUSE business to Meda

VIVUS, Inc. today announced that it has closed the sale of its MUSE business to Meda. Under the purchase agreement, Meda acquired the MUSE assets including the United States and foreign MUSE patents, existing inventory and the manufacturing facility located in Lakewood, New Jersey.

8 Nov 2010

VIVUS receives FDA CRL for QNEXA NDA

VIVUS, Inc. announced today that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for the investigational new drug QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The FDA issued the CRL to communicate its decision that the NDA cannot be approved in its present form.

29 Oct 2010

IMRT reduces gastrointestinal complications in prostate cancer patients

Prostate cancer patients who receive intensity modulated radiation therapy (IMRT) are less apt to suffer serious gastrointestinal complications following their treatment than those who receive three-dimensional conformal radiotherapy (CRT), according to new research from the University of Pennsylvania School of Medicine.

27 Oct 2010

Medicare reimbursement changes increase demand for intermittent catheters

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, reimbursement changes have caused the demand for intermittent catheters to increase significantly. In April 2008, Medicare changed reimbursement to cover up to 200 catheters per month, instead of the previous 4 that it covered.

26 Oct 2010

Robot-assisted surgery effective for five-year prostate cancer control: Study

A first-ever, long-term study of patients who underwent robot-assisted surgery to remove their cancerous prostates found that nearly 87 percent of them had no recurrence of the disease after five years.

19 Oct 2010

Kennedy Krieger Institute launches phase II clinical trial to investigate Revatio for DMD treatment

Kennedy Krieger Institute announced today the launch of a first‐of‐its‐kind, phase II clinical trial to investigate a treatment for heart disease in individuals with Duchenne muscular dystrophy (DMD).

13 Oct 2010

CDC, national leaders issue recommendations to standardize testosterone tests

The use of testosterone assays for patient care and research is on the rise as new research links testosterone to a variety of diseases and conditions. Although the assays are heavily used, discrepancies and inaccuracies in measurements resulting from the various assays are widespread.

11 Oct 2010

Vanderbilt-Ingram Cancer Center receives $7.6M ARRA stimulus grant for prostate cancer research

Vanderbilt-Ingram Cancer Center has received a $7.6 million American Recovery and Reinvestment Act of 2009 stimulus grant to coordinate a study comparing the effectiveness of various treatments for prostate cancer. David Penson, M.D., M.P.H., professor of Urologic Surgery, will serve as Principal Investigator for the Comparative Effectiveness Analysis of Surgery and Radiation study on prostate cancer.

8 Oct 2010

Erectile Dysfunction News and Research

Latest Erectile Dysfunction News and Research

American Medical Systems fourth quarter sales increase 0.7% to $147.0 million

Elis granted exclusive rights to market Apricus Bio's Vitaros in the Gulf and part of the Middle East

FDA approves Endo's FORTESTA Gel for low testosterone

VIVUS seeks marketing approval of QNEXA in the EU

VIVUS submits briefing document to FDA in effort to secure regulatory approval for QNEXA

Man Up Now capsules can dangerously lower blood pressure

VIVUS reports positive results from avanafil phase 3 study in erectile dysfunction

Apricus announces publication of NexACT technology data in Pharmaceutics Journal

Merck announces initial results from ISENTRESS Phase III study in HIV-1

Apricus files protocol of PrevOnco Phase 3 clinical trial for FDA SPA program

VYTORIN reduces major vascular events in patients with chronic kidney disease

NexACT technology improves oral delivery of five small molecule drugs

VIVUS closes sale of MUSE business to Meda

VIVUS receives FDA CRL for QNEXA NDA

IMRT reduces gastrointestinal complications in prostate cancer patients

Medicare reimbursement changes increase demand for intermittent catheters

Robot-assisted surgery effective for five-year prostate cancer control: Study

Kennedy Krieger Institute launches phase II clinical trial to investigate Revatio for DMD treatment

CDC, national leaders issue recommendations to standardize testosterone tests

Vanderbilt-Ingram Cancer Center receives $7.6M ARRA stimulus grant for prostate cancer research

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Erectile Dysfunction News and Research

Latest Erectile Dysfunction News and Research

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in